Brief Reports
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 15, 2003; 9(8): 1859-1862
Published online Aug 15, 2003. doi: 10.3748/wjg.v9.i8.1859
Expression of telomerase activity and oxidative stress in human hepatocellular carcinoma with cirrhosis
Dao-Yong Liu, Zhi-Hai Peng, Guo-Qiang Qiu, Chong-Zhi Zhou
Dao-Yong Liu, Department of General Surgery, Shanghai No.5 People’s Hospital, Shanghai 200240, China
Zhi-Hai Peng, Guo-Qiang Qiu, Chong-Zhi Zhou, Department of General Surgery, Shanghai First People’s Hospital, Shanghai 200080, China
Author contributions: All authors contributed equally to the work.
Supported by Science and Technology Foundation of Shanghai, No. 984119001
Correspondence to: Dr. Zhi-Hai Peng, Department of General Surgery, Shanghai First People’s Hospital, 85 Wujin Road, Shanghai 200080, China. pengpzhb@online.sh.cn
Received: March 4, 2003
Revised: April 23, 2003
Accepted: May 11, 2003
Published online: August 15, 2003

Abstract

AIM: To study the expression and significance of telomerase activity and oxidative stress in hepatocellular carcinoma (HCC) with cirrhosis.

METHODS: In this study, TRAP-ELISA assay was used to determine telomerase activity in 21 cases of HCC as well as in 23 cases of hepatic cirrhosis. Malondialdehyde (MDA), glutathione S-transferase (GST) and total anti-oxidative capacity (T-AOC) were also examined in the same samples with human MDA, GST and T-AOC kits.

RESULTS: Eighteen of 21 cases of HCC were found to have increased telomerase activity, whereas only three of the 23 non-cancerous cirrhotic samples were found to have weak telomerase activity, and the difference was significant (P < 0.001). No significant difference in telomerase activity was detected according to different tumor size, tumor stage, histological grade, HBsAg, contents of albumin, bilirubin, ALT, AFP, r-GT and platelet. There were significant differences between HCC and cirrhosis in the expression of MDA, GST and T-AOC respectively. Telomerase activity correlated positively with the content of MDA (P < 0.05).

CONCLUSION: Telomerase activation is the early event of carcinogenesis, which is not correlated with clinicopathological factors of HCC. The dysfunction of the anti-oxidative system is closely correlated with the progression from cirrhosis to hepatocellular carcinoma. Oxidative stress may contribute partly to telomerase activation.




INTRODUCTION

Telomeres correspond to the ends of eukaryotic chromosomes and are specialized structures containing unique (TTAGGG)n repeats[1]. Telomeres protect the chromosomes from DNA degradation, end to end fusions, rearrangements, and chromosome loss[2]. Because cellular DNA polymerases cannot replicate the 5’ end of the linear DNA molecule, the number of telomere repeats decreases (by 50-200 nucleotides/cell division) during aging of normal somatic cells. Shortening of telomeres may control the proliferative capacity of normal cells[3]. Telomerase, a ribonucleicacid-protein complex, adds hexameric repeats of 5’-TTAGGG-3’ to the end of telomeres to compensate for the progressive loss[4]. Although normal somatic cells do not express telomerase, immortalized cells such as tumor cells express this enzyme[5]. More recently, HeLa cells transfected with an antisense human telomerase were found to lose telomeric DNA and to die after 23 to 26 doublings[6]. Petersen et al[7] found that the rate of shortening of telomere restriction fragments in human fibroblasts could be accelerated significantly by oxidative stress. Importantly, after treatment of cells with short single stranded telomeric G-rich DNA fragments, glioblastoma cells recovered from the arrest and showed enhanced telomerase activity and elongated telomeres[8].

However, the mechanisms of activation and regulation of telomerase have not been establishednd. Cell line data indicate that a telomere length-dependent mechanism is the major pathway. On the other hand, normal lymphocytes up-regulate telomerase activity upon antigen and mitogen stimulation in vitro and in vivo. This indicates that telomere length-dependent mechanisms may be important or specific to different cell types for regulation of telomerase activation[9]. Only a few studies have specifically examined the relationship between telomerase activity in tumors and the status of oxidative stress. Our data implied that genetic defects in HCC facilitated the reactivation of telomerase activity, a process that might be associated with the increased expression of oxidative stress.

MATERIALS AND METHODS
Sample collection and processing

All 21 HCC specimens were sampled from patients who had undergone curative hepatectomy. Patients who had received radiotherapy or chemotherapy before operation were excluded. Liver cirrhosis tissues were obtained from those who had received hepatic biopsy in the operation for hypersplenia. Informed consent was obtained from all patients for subsequent use of their resected tissues. These specimens were immediately dissected into small pieces under aseptic condition within half an hour after removed, snap frozen in liquid nitrogen and stored at -80 °C until extracts for telomerase activity analysis and determination of oxidative stress.

Telomerase assay

Frozen tissue samples (100 µg) were homogenized in 500 µL of freshly made ice-cold lysis buffer. After 30 min incubation on ice, the lysate was centrifuged for 20 min at 16000 g, and the supernatant was transferred to fresh tubes and used as tissue extracts for the telomerase assay. The protein concentrations were determined. Telomerase activity was assayed by the TRAP-ELISA kit, a polymerase chain reaction (PCR)-based on an improved version of the original method described by Kim et al[10]. In brief, aliquots of tissue extract containing 40 µg protein were added to 50 µL reaction mixtures containing 0.1 µg substrate oligonucleotide (TS) primer, TSK (internal control) template. The reaction mixtures were incubated at 25 °C for 20 min and then amplified for 33 cycles of PCR at 94 °C for 30 s, at 50 °C for 30 s, and at 72 °C for 90 s, then preserved at 4 °C for ELISA reaction process. 5 µg PCR product was taken for ELISA reaction. The value at A450 was read within 30 min. Telomerase activity equaled A450 for experimental well minus A450 for control well. The strength of telomerase activity was defined as follows: ++, > 0.4; +, > 0.2; -, < 0.2.

MDA, GST and T-AOC determination

Frozen tissue samples (100 mg) were homogenized in 1.0 mL, the homogenized samples were centrifuged for 15 min at 3000 r/min, and the supernatant was transferred to fresh tubes. After the protein concentrations were determined, MDA, GST and T-AOC were assayed with human MDA, GST and T-AOC kit (Jiancheng Biological Technical Institute, Nanjing, China).

Statistics analysis

Contingency table methods were used to analyze the univariate association between telomerase activity and clinicopathological data (age, sex, tumor grade, tumor size, and liver status). Significance was confirmed by Fisher’s exact test. The association between telomerase activity and oxidative stress was investigated by Pearson correlation analysis test. All calculations were performed using the SPSS version 10.0 statistical software package, and the results were considered statistically significant at P < 0.05.

RESULTS
Telomerase activity in HCC and hepatic cirrhosis

Telomerase positive cells were used as a positive control for assessing telomerase activity in clinical specimens. We measured telomerase activity in surgically resected specimens from 21 cases of HCC and 23 cases of liver cirrhotic tissue. Telomerase activity was detected in 18 of the 21 HCC specimens (85.7%), but it was detected only in 3 of 23 samples of liver cirrhosis (13.4%). There was a significant difference in telomerase activity between HCC and hepatic cirrhosis (P < 0.001). There was no significant difference in telomerase activity in regard to different tumor size, tumor stage, histological grade, HBsAg, contents of albumin, bilirubin, ALT, AFP, r-GT and platelet (Table 1).

Table 1 Relationship between telomerase activity and clinico-pathologic factors in HCC.
Telomerase activity
HighLow or lossP value
Tumor size (cm)7.7 ± 3.57.1 ± 3.60.664
Tumor grade (high/low)9/44/40.245
Tumor stage (early/ advanced)6/73/50.327
ALT (normal /abnormal)9/26/40.212
Bilirubin (normal /elevated)9/29/10.414
Platelet (normal/ decreased)9/27/30.324
HbsAg (positive/negetive)6/57/30.272
AFP (> 400U/< 400U)7/55/50.309
Albumin (g/L)39.2 ± 5.639.3 ± 4.20.946
Globulin (g/L)28.6 ± 5.326.8 ± 6.50.423
γ-GT(U)115.2 ± 98.7108.9 ± 69.50.814
Expression of MDA, GST and T-AOC in HCC and hepatic cirrhosis

The content of MDA was 84.76 ± 26.98 nM/mL in HCC, while it was 49.49 ± 23.03 nM/mL in hepatic cirrhosis, and the difference was significant between them (P < 0.001). Nevertheless, the contents of GST and T-AOC were lower in HCC than those in hepatic cirrhosis (P < 0.001)( Table 2).

Table 2 Expression of MDA, GST and T-AOC ( -x±s).
HCCCirrhosisP value
MDA (nM/mL)84.76 ± 26.9849.49 ± 23.03< 0.001
GST (U/mg)8.18 ± 5.5918.70 ± 5.20< 0.001
T-AOC (U/mg)0.257 ± 0.2410.689 ± 0.302< 0.001
Telomerase activity and content of MDA

The relationship between telomerase activity and oxidative stress was investigated by Pearson correlation analysis. Tumor specimes with a higher level of MDA expressed increased telomerase activity (r = 0.496, P < 0.05).

DISCUSSION

HCC is the most common solid tumor worldwide, being responsible for more than 1 million deaths annually, especially in Eastern Asia and South Africa[11], which ranks eigthth in frequency among cancers in the world[12]. It is one of the few human cancers in which an underlying etiology can be identified in most cases, and has a background of chronic inflammatory liver disease caused by viral infection that induces cirrhosis[13]. However, it is not clear how these disorder results in HCC. The reactivation of telomerase activity may play a significant role in hepatocarcinogenesis.

Telomerase is a ribonucleoprotein complex[14] that is thought to add telomeric repeats onto the ends of chromosomes during the replicative phase of the cell cycle. Telomeres have classically been regarded as a simple linear structure, possibly capped by specific proteins. However, this simple structural view was challenged. Recent data have shown that the structure of human telomeres might be more complicated than originally thought[15]. Three different mechanisms were currently thought to contribute to telomere shortening: the so-called end replication problem, the C-strand degradation model and single-strand damage[16]. Both the end replication problem and the C-strand degradation model of telomere shortening do not take into account the possibility that the shortening rate of telomeres depends on external influences, especially oxidative stress-dependent DNA damage. von Zglinicki et al[17] demonstrated that the telomere shortening rate could be either accelerated or decelerated by a modification of the amount of oxidative stress.

Recently, a highly sensitive PCR based TRAP assay for measuring telomerase activity that also includes an improved method of detergent lysis has been developed[10]. This assay allows more uniform extraction of telomerase from a small number of cells than conventional techniques, in which telomerase first synthesizes extension products that then serve as templates for PCR amplification. The simplicity and increased sensitivity of this assay have resulted in a dramatic increase in the investigation of telomerase expression. In this study, telomerase activity was positive in 18 of 21 HCC specimens (85.7%), which suggested that telomerase activation was a universal event in human hepatocellular carcinoma. However, undetectable telomerase activity has been reported by others in about 10% of tumors samples[18,19]. Some immortal cell lines without detectable telomerase activity have been described that were characterized by long and heterogenous telomeres[20,21]. These observations might indicate the presence of a telomerase-independent mechanism for telomere length maintenance in these tumors.

It is well documented that telomerase activity is detectable in the majority of cancers but rarely in normal somatic tissue. Some studies have demonstrated that some types of somatic cells express low levels of telomerase activity[22-24]. In particular physiologically regenerating somatic cells, such as hematopoietic cells, epithelial cells of skin or intestine, and endometrial cells, have been shown low levels of telomerase activity. In this study, low telomerase activity was detected in 3 of 23 cirrhotic specimens. One possible explanation for this finding was that these cirrhotic tissue samples may also contained probable cancer cell, infiltration of lymphoid cells, or dysplasia cells. Finally, demographic and clinical information of patients, such as tumor size, tumor stage, histological grade, HBsAg, albumin, bilirubin, ALT, AFP, r-GT and platelet were not correlated with the telomerase activity.

Many lines of evidence indicate that telomerase is reversibly regulated[25]. Resting lymphocytes express little telomerase activity, but stimulation of specific antigen receptors on the cell plasma membrane markedly increases telomerase activity[26-29]. High-level sun light exposure of normal human skins results in an increased incidence of telomerase activation[30]. Human hematopoietic cells with γ-rays[31], or human carcinoma cell lines with X-rays[32] induce the activation of telomerase. Activated telomerase in cancer cells is repressed when the cells leaves the cell cycle and become quiescent[33-37]. Nevertheless, the mechanisms of telomerase regulation, such as its suppression in normal human somatic cells and activation in neoplastic cells, are far from established.

Telomeres are believed to protect the ends of chromosomes against exonuclease and ligases, to prevent the activation of DNA-damage checkpoints, and to counteract loss of terminal DNA-segments that occurs when linear DNA is replicated[2,38,39]. Oikawa et al[40,41] demonstrated that oxidative stress induced DNA damage at the 5’ site of 5’-GGG-3’ in the telomere sequence, and the telomeric G triplet was especially sensitive to cleavage by oxidative damage. Moreover, it was shown that oxidative stress increased the frequency of S1 nuclease-sensitive sites, especially in telomeres[42,43]. However, it was unknown whether oxidative stress was associated with the telomerase activity in human tissue specimens. In this study, the expression of malondialdehyde, glutathione S-transferase and total anti-oxidative capacity were examined in the same samples. There were higher levels of the expression of glutathione S-transferase and total anti-oxidative capacity in hepatic cirrhosis specimens, while enhanced expression of malondialdehyde was found in HCC specimens. The difference between HCC and hepatic cirrhosis was significant (P < 0.05). These findings suggested that the dysfunction of the anti-oxidative system was closely correlated with the progression from hepatic cirrhosis to hepatocellular carcinoma. Other studies also showed that HCC patients with higher anti-oxidative capacity levels survived longer after hepatectomy[44].

Henle et al[41] found that the telomeric G triplet was especially sensitive to cleavage by oxidative damage. In MRC-5 fibroblasts and U87 glioblastoma cells, oxidative stress-mediated production of single-strand damage in telomeres was concomitant to cell cycle arrest. This response can be modeled by treatment of cells with short single stranded telomeric G-rich DNA fragments. Recovery from it is accompanied by up-regulation of telomerase activity and elongation of telomeres[45]. The gene transcription of TERT is an essential rate-limiting step in telomerase activation and may be subjected to multiple levels of control and regulated by different factors in different cellular contexts[46]. In the present study we found that telomerase activity correlated positively with the content of MDA (P < 0.05). One possible explanation for this observation was that telomere shortening might be accelerated by oxidative stress when telomere reached critical length, which caused the gene transcription of TERT, and telomerase was activated. Buchkovich et al[47] first demonstrated that in primary human leukocytes stimulated with phytohemagglutinin, telomerase activity was increased by more than 10-fold as naturally quiescent cells entered the cell cycle. In an animal model, treatment with an antagonist of growth hormone-releasing hormone dramatically decreased telomerase activity in xenografted U-87-MG human glioblastoma cells[46]. Their research was the first demonstration of a signaling pathway in normal cells that regulated telomerase, and paved the way for experimental analysis of “upstream” regulators. The possibility of a relationship between upstream regulators and oxidative stress is an important issue for future experimental studies on control of telomerase activity.

Although tumor cells have a much shorter telomere length, telomeres shorten with rates between 15 and 76 bp/PD in different culture. Too much time[48] is needed to reach the critical length of telomeres in tumor cells. However, oxidative stress may increase the rate of telomere shortening by the site-specific DNA damage in the telomere sequence. Thus, combination treatment[7] of oxidative stress and telomerase inhibitor in cancer cells will accelerate greatly the telomere shortening. Telomeres might shorten quickly to the point which is no longer able to divide.

Footnotes

Edited by Zhang JZ

References
1.  Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569-573.  [PubMed]  [DOI]
2.  de Lange T. Activation of telomerase in a human tumor. Proc Natl Acad Sci U S A. 1994;91:2882-2885.  [PubMed]  [DOI]
3.  Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458-460.  [PubMed]  [DOI]
4.  Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43:405-413.  [PubMed]  [DOI]
5.  Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley CB, Lansdorp PM. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 1996;14:239-248.  [PubMed]  [DOI]
6.  Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J. The RNA component of human telomerase. Science. 1995;269:1236-1241.  [PubMed]  [DOI]
7.  Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res. 1998;239:152-160.  [PubMed]  [DOI]
8.  Saretzki G, Sitte N, Merkel U, Wurm RE, von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene. 1999;18:5148-5158.  [PubMed]  [DOI]
9.  Norrback KF, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood. 1996;88:222-229.  [PubMed]  [DOI]
10.  Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.  [PubMed]  [DOI]
11.  Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol. 2002;8:193-199.  [PubMed]  [DOI]
12.  Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454.  [PubMed]  [DOI]
13.  Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353:1253-1257.  [PubMed]  [DOI]
14.  Meyne J, Ratliff RL, Moyzis RK. Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci U S A. 1989;86:7049-7053.  [PubMed]  [DOI]
15.  Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503-514.  [PubMed]  [DOI]
16.  von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci. 2000;908:99-110.  [PubMed]  [DOI]
17.  von Zglinicki T, Pilger R, Sitte N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med. 2000;28:64-74.  [PubMed]  [DOI]
18.  Hsieh HF, Harn HJ, Chiu SC, Liu YC, Lui WY, Ho LI. Telomerase activity correlates with cell cycle regulators in human hepatocellular carcinoma. Liver. 2000;20:143-151.  [PubMed]  [DOI]
19.  Shoji Y, Yoshinaga K, Inoue A, Iwasaki A, Sugihara K. Quantification of telomerase activity in sporadic colorectal carcinoma: association with tumor growth and venous invasion. Cancer. 2000;88:1304-1309.  [PubMed]  [DOI]
20.  Rogan EM, Bryan TM, Hukku B, Maclean K, Chang AC, Moy EL, Englezou A, Warneford SG, Dalla-Pozza L, Reddel RR. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol. 1995;15:4745-4753.  [PubMed]  [DOI]
21.  Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996;16:53-65.  [PubMed]  [DOI]
22.  Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S, Yamakido M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 1995;155:3711-3715.  [PubMed]  [DOI]
23.  Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, Ide T, Utakoji T. Telomerase activity in normal human epithelial cells. Oncogene. 1996;13:433-439.  [PubMed]  [DOI]
24.  Kyo S, Takakura M, Kohama T, Inoue M. Telomerase activity in human endometrium. Cancer Res. 1997;57:610-614.  [PubMed]  [DOI]
25.  Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999;13:2091-2104.  [PubMed]  [DOI]
26.  Igarashi H, Sakaguchi N. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. Blood. 1997;89:1299-1307.  [PubMed]  [DOI]
27.  Hu BT, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol. 1997;159:1068-1071.  [PubMed]  [DOI]
28.  Hathcock KS, Weng NP, Merica R, Jenkins MK, Hodes R. Cutting edge: antigen-dependent regulation of telomerase activity in murine T cells. J Immunol. 1998;160:5702-5706.  [PubMed]  [DOI]
29.  Weng NP, Hathcock KS, Hodes RJ. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity. 1998;9:151-157.  [PubMed]  [DOI]
30.  Ueda M, Ouhtit A, Bito T, Nakazawa K, Lübbe J, Ichihashi M, Yamasaki H, Nakazawa H. Evidence for UV-associated activation of telomerase in human skin. Cancer Res. 1997;57:370-374.  [PubMed]  [DOI]
31.  Leteurtre F, Li X, Gluckman E, Carosella ED. Telomerase activity during the cell cycle and in gamma-irradiated hematopoietic cells. Leukemia. 1997;11:1681-1689.  [PubMed]  [DOI]
32.  Hyeon Joo O, Hande MP, Lansdorp PM, Natarajan AT. Induction of telomerase activity and chromosome aberrations in human tumour cell lines following X-irradiation. Mutat Res. 1998;401:121-131.  [PubMed]  [DOI]
33.  Sharma HW, Sokoloski JA, Perez JR, Maltese JY, Sartorelli AC, Stein CA, Nichols G, Khaled Z, Telang NT, Narayanan R. Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci USA. 1995;92:12343-12346.  [PubMed]  [DOI]
34.  Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol. 1996;16:2932-2939.  [PubMed]  [DOI]
35.  Bestilny LJ, Brown CB, Miura Y, Robertson LD, Riabowol KT. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res. 1996;56:3796-3802.  [PubMed]  [DOI]
36.  Xu D, Gruber A, Peterson C, Pisa P. Supression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia. 1996;10:1354-1357.  [PubMed]  [DOI]
37.  Savoysky E, Yoshida K, Ohtomo T, Yamaguchi Y, Akamatsu K, Yamazaki T, Yoshida S, Tsuchiya M. Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells. Biochem Biophys Res Commun. 1996;226:329-334.  [PubMed]  [DOI]
38.  Morin GB. Is telomerase a universal cancer target. J Natl Cancer Inst. 1995;87:859-861.  [PubMed]  [DOI]
39.  Sharma HW, Maltese JY, Zhu X, Kaiser HE, Narayanan R. Telomeres, telomerase and cancer: is the magic bullet real. Anticancer Res. 1996;16:511-515.  [PubMed]  [DOI]
40.  Oikawa S, Kawanishi S. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Lett. 1999;453:365-368.  [PubMed]  [DOI]
41.  Henle ES, Han Z, Tang N, Rai P, Luo Y, Linn S. Sequence-specific DNA cleavage by Fe2+-mediated fenton reactions has possible biological implications. J Biol Chem. 1999;274:962-971.  [PubMed]  [DOI]
42.  von Zglinicki T, Saretzki G, Döcke W, Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence. Exp Cell Res. 1995;220:186-193.  [PubMed]  [DOI]
43.  Sitte N, Saretzki G, von Zglinicki T. Accelerated telomere shortening in fibroblasts after extended periods of confluency. Free Radic Biol Med. 1998;24:885-893.  [PubMed]  [DOI]
44.  Lin MT, Wang MY, Liaw KY, Lee PH, Chien SF, Tsai JS, Lin-Shiau SY. Superoxide dismutase in hepatocellular carcinoma affects patient prognosis. Hepatogastroenterology. 2001;48:1102-1105.  [PubMed]  [DOI]
45.  Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene. 1999;232:97-106.  [PubMed]  [DOI]
46.  Kiaris H, Schally AV. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1999;96:226-231.  [PubMed]  [DOI]
47.  Buchkovich KJ, Greider CW. Telomerase regulation during entry into the cell cycle in normal human T cells. Mol Biol Cell. 1996;7:1443-1454.  [PubMed]  [DOI]
48.  Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, Liu J, Haqqi T, Nishiyama A, Villeponteau B. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J. 1998;12:801-811.  [PubMed]  [DOI]